February 6, 2026
Ocumetics Technology announced 3-month postop data from its first patients implanted with its accommodating IOL, the Ocumetics Lens. According to the company’s press release, “Group 1 data met or exceeded all predefined internal benchmarks for safety, lens delivery, and foundational distance visual acuity performance,” which the company noted will allow it to progress in its clinical program. Patients in group 1 had “severe visual impairment” with some at 20/250 UDVA.